A Study of the Effects of Minocycline on Cognitive Function After Carotid Endarterectomy

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Carotid Stenosis

In brief

The primary aim of this protocol is to investigate a possible new, neuroprotective treatment to prevent cognitive deficits that occur after carotid endarterectomy. We will investigate whether a widely used antibiotic agent - minocycline - that has shown neuroprotective effects in animal models of neurological diseases - can reduce the cognitive deficits associated with the surgical procedure of carotid endarterectomy (CEA). Because these cognitive deficits are believed to be a result of small strokes (due to emboli and/or hypoperfusion), this study will provide preliminary data on the use of this drug as a neuroprotective agent in stroke - a leading cause of disability. (1) The first aim of this study is to examine whether 5 doses of minocycline administered 36 hrs before and 1 dose 12 hrs after the surgical procedure in patients undergoing CEA are effective to reduce the cognitive deficits associated with this procedure as compared with placebo. a. The null hypothesis is that there is no difference in cognitive performance changes after CEA between the patients that receive placebo or minocycline.

Key facts

Study ID

NCT00401921

Run by

Brigham and Women's Hospital

People needed

0

Starts

2006-10-01

Expected to finish

2010-06-01

Last updated by the study team

2017-07-14

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with carotid stenosis 60% or more with a clinical indication of CEA.
• Patients that can perform the tests in English.
• Women of childbearing age must be non-lactating and surgically sterile or using an effective method of birth control and have a negative pregnancy test (adequate birth control includes use of intra uterine device, or a barrier method, e.g. condom, diaphragm).
• Ages Eligible for Study: 18 Years - 90 Years
• Genders Eligible for Study: Both

You may not qualify if…

• Known hypersensitivity to tetracyclines
• Advanced cardiac, pulmonary or renal disease as assessed by the PCP of the patient.
• Previous strokes with important clinical neurological deficits.
• Pregnancy, breast-feeding or lactating
• Baseline MMSE score less or equal to 20.
• Female subjects on oral contraceptives.

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.